Aspirin for Primary Prevention of Cardiovascular Events in Diabetes: Still an Open Question

This JAMA editorial highlights the uncertainty in the use of aspirin in primary prevention for people with diabetes.

Hopefully the Ascend Trial will help to answer this question.

Below, the Exeter Drugs update (Co-authored by KMM) expands on this issue taking a look at the recently published evidence in the POPADAD and JPAD trials:

Exeter Drugs Update

View more documents from PeninsulaEndocrine.